Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BenevolentAI Limited
In a crowded AI-driven drug development sector, BenevolentAI stands out with its broad pipeline of drug candidates, deep pockets, and a growing partnership with AstraZeneca. Ivan Griffin, company co-founder and chief operating officer spoke with In Vivo about the formula behind the company’s successes.
AI is beginning to transform biologics discovery. The power of algorithms used in biologics discovery has increased over the last decade, and today between 50 and 60 AI-enabled biologics are in different stages of discovery, preclinical and clinical development. We expect the number of AI-enabled biologics to continue to grow rapidly, driven by advances in AI technology and algorithms, growing computing power, increasing availability of data, and evolving discovery workflows. We show that the volume of data used for training algorithms in biologics discovery is increasing exponentially over time, a trend reminiscent of Moore’s Law in computer technology.
The new head of South Korea’s AI Drug Development Support Center talks about the country’s activities and market trends in the field, why the otherwise tech-savvy country is still lagging and what is needed to boost collaboration and the availability of big data.
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
- Artificial Intelligence
- Drug Discovery Tools
- Other Names / Subsidiaries
- BenevolentBio, BenevolentTech
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.